YAP1 and SCML2 interaction in prostate cancer
Official title: Crosstalk between YAP1 and Polycomb Group Protein SCML2 in Prostate Cancer
Funded at Clark Atlanta University · NIH-11325049 · Data updated 2026-11-12
Researchers are studying how two proteins, YAP1 and SCML2, work together in aggressive prostate cancer to understand why some forms resist therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clark Atlanta University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | June 1, 1997 |
| Project end | March 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $187,931 |
| NIH project number | 5U54MD007590-39 |
| Project ID | NIH-11325049 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced or metastatic prostate cancer, especially those with castration-resistant disease and African American men.
✕Less likely to help
Patients with early, localized prostate cancer or non-prostate cancers are unlikely to benefit from this specific research.
What this research studies
This project looks at how YAP1 and SCML2 interact at the molecular level in prostate cancer cells, especially in cases that resist standard treatments. Using proteomics, scientists will identify how these proteins bind and how androgen signaling affects their partnership in different disease states. They will also test what happens when SCML2 is removed in sensitive and resistant cancer cells to see if it changes growth or drug response. The goal is to uncover mechanisms that could be targeted to slow progression and improve therapies for patients, particularly among African American men who are disproportionately affected.
Why it matters
Potential benefit: If successful, the work could reveal new targets to develop more effective treatments for advanced prostate cancer.
How similar studies have gone: Previous research has shown that YAP1 and related pathways can influence cancer cell behavior, supporting the potential of this approach.
Where this research is happening
-
Clark Atlanta University
Atlanta, United States Active
Researchers
- Principal investigator: Cinar, Bekir — Clark Atlanta University
- Study coordinator: Cinar, Bekir
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.